SCHEMBL7108707

SCHEMBL7108707

CN(C)S(=O)(=O)Nc1cc(C(O)CNCCOc2ccc3c(c2)oc2ccccc23)ccc1OCc1ccccc1

nearest known ligand 0.44

Predicted protein targets (top 6)

geneUniProtsupporting neighboursconfidence
ADRB3 P13945 6/20 0.44
ADRB2 P07550 4/20 0.42
BCHE P06276 8/20 0.40
ACHE P22303 5/20 0.40
ADRA1A P35348 1/20 0.40
MAOB P27338 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL7107952 0.92 ADRB3 (0.48) ADRB3ADRA1A
SCHEMBL7979311 0.89 ADRB3 (0.42) ADRB3ADRB2BCHEACHEADRA1A
SCHEMBL7979314 0.89 ADRB3 (0.42) ADRB3ADRB2BCHEACHEADRA1A
SCHEMBL6913329 0.88 ADRB3 (0.48) ADRB3ADRB2ADRA1A
SCHEMBL6906532 0.88 ADRB3 (0.48) ADRB3ADRB2ADRA1A
SCHEMBL6906536 0.88 ADRB3 (0.48) ADRB3ADRB2ADRA1A
SCHEMBL7117615 0.87 BCHE (0.37) ADRB3BCHEACHEMAOB
Hydrochloric Acid SCHEMBL7113387 0.87 ADRB3 (0.49) ADRB3ADRB2ADRA1A
Hydrochloric Acid SCHEMBL7105698 0.87 ADRB3 (0.49) ADRB3ADRB2ADRA1A
Hydrochloric Acid SCHEMBL7113393 0.87 ADRB3 (0.49) ADRB3ADRB2ADRA1A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-0882707-B1 NOVEL TRICYCLIC COMPOUNDS AND DRUG COMPOSITIONS CONTAINING THE SAME ASAHI CHEMICAL IND (JP) 2003-10-08 EP disclosed
US-20030139475-A1 Novel tricyclic compounds and drug compositions containing same ASAHI KASEI KOGYO KABUSHIKI KAISHA (JP) 2003-07-24 US disclosed
US-6545053-B1 Aminoethoxyfluorene derivatives are beta-3 adrenaline receptor agonists and are useful as drugs for the treatment and prevention of diabetes, obesity, hyperlipemia, etc. ASAHI KASEI KOGYO KABUSHIKI KAISHA (JP) 2003-04-08 US disclosed
US-6187809-B1 BETA-3 ADRENALINE RECEPTOR AGONIST DRUGS FOR THE TREATMENT OF DIABETES, OBESITY, AND HYPERLIPEMIA; 2-(N-(2-(DIBENZOFURAN-3-YLOXY)ETHYL)AMINO)-1-PHENYLETHANOL, FOR EXAMPLE ASAHI KASEI KOGYO KABUSHIKI KAISHA (JP) 2001-02-13 US disclosed
US-6037362-A CARBAZOLE DERIVATIVES; DEPROTECTING, AMINATION; ANTILIPEMIC AND ANTIDIABETIC AGENTS; B-ADRENALINE RECEPTOR AGONISTS; DIETETICS ASAHI KASEI KOGYO KABUSHIKI KAISHA (JP) 2000-03-14 US disclosed
EP-0882707-A1 NOVEL TRICYCLIC COMPOUNDS AND DRUG COMPOSITIONS CONTAINING THE SAME Asahi Kasei Kogyo Kabushiki Kaisha (JP) 1998-12-09 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20030139475-A1 Novel tricyclic compounds and drug compositions containing same ADRB3, MC2R, NR3C1 ADRB3 1/4885ADRB2 14/4885BCHE 698/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.